TSPO: Translocator protein
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme.
- Drugs that act on it: 3
- Approved: 1
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TSPO, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
| AlpidemWithdrawn | Approved | — | Small molecule | Partial agonistTranslocator protein partial agonist | 0 |
| Emapunil | Phase 2 | Novartis Pharmaceuticals | Small molecule | AgonistTranslocator protein agonist | 1 |
| ONO-2952 | Phase 2 | Ono Pharmaceutical | Small molecule | AntagonistTranslocator protein antagonist | 0 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Role of a Mitochondrial Receptor in Blood Sugar Regulation | Emapunil | Phase 2 | Recruiting | Imperial College London | Jul 2, 2026 |
- Neurodegenerative disease0.46
- Alzheimer disease0.40
- Anxiety disorder0.39
- Parkinson disease0.39
- Lysosomal storage disease0.36
- Autoimmune disorder of central nervous system0.25
- Neoplasm0.12
- Prostate carcinoma0.12
- Glioblastoma0.12
- Central nervous system cancer0.12
- Glioma0.12
- Major depressive disorder0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5742, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P30536, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets